Protara Therapeutics, Inc. (TARA) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 New York City, NY, 美国. 现任CEO为 Jesse Shefferman.
TARA 拥有 IPO日期为 2014-10-22, 28 名全职员工, 在 NASDAQ Global Market, 市值为 $201.05M.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
